Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers

Sci Rep. 2019 Aug 23;9(1):12322. doi: 10.1038/s41598-019-48774-1.

Abstract

Proteome-centric studies, although have identified numerous lncRNA-encoded polypeptides, lack differential expression analysis of lncRNA-peptidome across primary tissues, cell lines and cancer states. We established a computational-proteogenomic workflow involving re-processing of publicly available LC-MS/MS data, which facilitated the identification of tissue-specific and universally expressed (UExp) lncRNA-polypeptides across 14 primary human tissues and 11 cell lines. The utility of lncRNA-peptidome as cancer-biomarkers was investigated by re-processing LC-MS/MS data from 92 colon-adenocarcinoma (COAD) and 30 normal colon-epithelium tissues. Intriguingly, a significant upregulation of five lncRNA UExp-polypeptides in COAD tissues was observed. Furthermore, clustering of the UExp-polypeptides led to the classification of COAD patients that coincided with the clinical stratification, underlining the prognostic potential of the UExp-polypeptides. Lastly, we identified differential abundance of the UExp-polypeptides in the plasma of prostate-cancer patients highlighting their potential as plasma-biomarker. The analysis of lncRNA-peptidome may pave the way to identify effective tissue/plasma biomarkers for different cancer types.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / genetics
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics*
  • Cell Line
  • Colonic Neoplasms / blood
  • Colonic Neoplasms / genetics
  • Humans
  • Male
  • Neoplasms / blood*
  • Neoplasms / genetics*
  • Organ Specificity
  • Peptides / blood*
  • Prognosis
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / genetics
  • Proteogenomics
  • Proteome / metabolism*
  • RNA, Long Noncoding / blood*

Substances

  • Biomarkers, Tumor
  • Peptides
  • Proteome
  • RNA, Long Noncoding